Arbutus Biopharma Corporation — Company profile
Healthcare · Biotechnology · United States
Last price 4.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 832.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Details
| Name | Arbutus Biopharma Corporation |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 19 |
| Founded | 2005 |
| Ceo | Lindsay Androski |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | CA03879J1003 |
| Cusip | 03879J100 |
| Cik | 0001447028 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Lindsay Androski J.D., M.B.A. | President, Chief Executive Officer and Chairman |
| Tuan Nguyen | Chief Financial Officer |
| Andrew J. Sung | General Counsel |
| R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary |
Contact
| Address | 701 Veterans Circle, Warminster, Pennsylvania 18974, United States |
| Phone | 267 469 0914 |
| Website | https://www.arbutusbio.com |